1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.

[1]  Harlan M Krumholz,et al.  2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa , 2016, Journal of the American College of Cardiology.

[2]  D. Atar,et al.  Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint , 2016, Journal of the American Heart Association.

[3]  P. Serruys,et al.  Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity: Patient-Level Pooled Analysis of 6081 Patients , 2016, Circulation. Cardiovascular interventions.

[4]  P. Armstrong,et al.  Transatlantic Comparison of ST-Segment Elevation Myocardial Infarction Guidelines: Insights From the United States and Europe. , 2016, Journal of the American College of Cardiology.

[5]  Sunil V. Rao,et al.  Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial , 2016, The Lancet.

[6]  A. Lincoff.  What Role for Glycoprotein IIb/IIIa Inhibition in Contemporary Coronary Intervention? , 2015, JACC. Cardiovascular interventions.

[7]  H. Thiele,et al.  Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. , 2015, Vascular pharmacology.

[8]  Marc P. Bonaca,et al.  Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction , 2015, Circulation.

[9]  P. Kolh,et al.  2014 ESC/EACTS guidelines on myocardial revascularization. , 2015, Revista espanola de cardiologia.

[10]  V. Fuster,et al.  Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial. , 2014, Journal of the American College of Cardiology.

[11]  Holger Thiele,et al.  Comprehensive prognosis assessment by CMR imaging after ST-segment elevation myocardial infarction. , 2014, Journal of the American College of Cardiology.

[12]  E. Omerovic,et al.  Outcomes 1 year after thrombus aspiration for myocardial infarction. , 2014, The New England journal of medicine.

[13]  G. De Luca,et al.  Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: a meta-regression analysis of 30 randomized trials. , 2014, Atherosclerosis.

[14]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[15]  H. Thiele,et al.  Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[16]  G. Patti,et al.  Antiplatelet therapy in patients with diabetes mellitus and acute coronary syndrome. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[17]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.

[18]  G. Stone,et al.  Intralesional Abciximab and Thrombus Aspiration in Patients With Large Anterior Myocardial Infarction: One-Year Results From the INFUSE-AMI Trial , 2013, Circulation. Cardiovascular interventions.

[19]  G. Schuler,et al.  Intracoronary versus intravenous abciximab bolus in patients with ST-segment elevation myocardial infarction: 1-year results of the randomized AIDA STEMI trial. , 2013, Journal of the American College of Cardiology.

[20]  F. Eberli,et al.  Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease Final 5-Year Report (Limus Eluted From A Durable Versus ERodable Stent Coating) Randomi , 2022 .

[21]  G. Schuler,et al.  Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial. , 2013, Journal of the American College of Cardiology.

[22]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[23]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[24]  G. Schuler,et al.  Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial , 2012, The Lancet.

[25]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[26]  S. Pedersen,et al.  Intracoronary Compared to Intravenous Abciximab in Patients with ST Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention Reduces Mortality, Target Vessel Revascularization and Reinfarction after 1 Year , 2011, Cardiology.

[27]  Han Wu,et al.  Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis , 2011, PloS one.

[28]  Matthias Gutberlet,et al.  Long-term prognostic value of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction , 2011, Heart.

[29]  F. Van de Werf,et al.  Myocardial salvage by CMR correlates with LV remodeling and early ST-segment resolution in acute myocardial infarction. , 2010, JACC. Cardiovascular imaging.

[30]  S. Stevens,et al.  Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial , 2010, European heart journal.

[31]  G. Schuler,et al.  Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction. , 2010, Journal of the American College of Cardiology.

[32]  J. Kaski,et al.  Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations. , 2009, Atherosclerosis.

[33]  E. Antman,et al.  Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[34]  Christopher P Cannon,et al.  Diabetes and mortality following acute coronary syndromes. , 2007, JAMA.

[35]  Deepak L. Bhatt,et al.  Abciximab reduces mortality in diabetics following percutaneous coronary intervention. , 2000, Journal of the American College of Cardiology.